• Recombinant Vector Vaccine Development for SARS-CoV-2

The emergence and outbreak of emerging infectious diseases is a global challenge to public health. At present, scientists from academia and biopharmaceutical industries around the world are working hard to find ways to prevent and treat coronavirus infections. Creative Biostructure has rapidly integrated related businesses characterized by structural biology and currently provides preclinical development services for recombinant vector vaccines to meet the urgent needs of SARS-CoV-2 vaccine R&D. Recombinant Vector Vaccine Development for SARS-CoV-2

  • 6
  • Uploaded 08/02/20 at 09:24AM
Login to add to your favorite
Add to Favorite
Add to you Site
The link to this page is:

You can add this media player into your website:

Send Friend Request x